Bilateral Uterine Arteries Methotrexate Infusion and Embolization: A New Approach in Patient with Caesarean Scar Pregnancy: Case Report and Literature Review

Massimiliano Natrella¹, Alessandro Messina², Bianca Masturzo², Raphael Thommaset³, Raffaele Tinelli⁴, Alessandro Libretti⁵, Livio Leo³*

¹Department of Radiology, Hopital Parini, AUSL Valleè d'Aoste, Aosta, Italy
²University of Turin, Department of Gynecology and Obstetrics, Degli Infermi Hospital, Ponderano, Biella, Italy
³Department of Gynecology and Obstetrics, Hopital Beauregard, AUSL Valleè d'Aoste, Aosta, Italy
⁴Department of Obstetrics and Gynecology, “Valle d’Itria” Hospital, Martina Franca, Taranto, Italy
⁵Department of Obstetrics and Gynecology, University Hospital Maggiore della Carità, Novara, Italy

*Corresponding author: Livio Leo, Division of Obstetrics and Gynecology, Hopital Beauregard, AUSL Valleè d’Aoste, 11100 Aosta, Italy; lleo@ausl.vda.it


Received: 12 April 2024, Accepted: 17 April 2024, Published: 19 April 2024

Abstract

Background: Cesarean scar pregnancy (CSP) is a rare ectopic pregnancy implanted in the myometrium within the site of a previous Cesarean scar. It is associated with severe complications, such as placental implantation, uterine rupture with uncontrolled hemorrhage, infertility or even death.

Case Presentation: A 38-year-old woman, G3P1, underwent a routine early pregnancy scan in Aosta Beauregard Hospital in October 2022. After a transvaginal ultrasound, she was diagnosed with a cesarean scar pregnancy. We present a review of the literature about CSP and our case, successfully treated with uterine artery methotrexate (MTX) infusion and embolization.

Discussion: Due to the rarity of CSP, the optimal treatment has not been already established. The surgical approach was considered the only possible treatment of these cases but, as most of these women may wish to conceive again, it may be necessary to found conservative treatment options in order to reserve the non-conservative modality just for cases of uncontrolled bleeding.
Keywords: Scar Pregnancy; Uterine artery embolization; Methotrexate infusion.

Introduction

In recent years, due to the increase in the rate of caesarean sections, there has been a major interest in the study of the complications of hysteroscopy, including placenta anomalies, uterine rupture and Cesarean Scar Pregnancy (CSP) [1]. CSP accounts for approximately 6% of all ectopic pregnancies in women who have undergone at least one caesarean section [2]. In caesarean scar pregnancy, the pregnancy is implanted in the myometrium at the site of the previous Cesarean scar. It is associated with severe complications, such as placental implantation, uterine rupture with uncontrolled hemorrhage, infertility or even death [3,4]. CSP is characterized by the presence of a gestational sac in the anterior uterine wall, resulting in a reduction in the thickness of the wall between the gestational sac and the bladder and the presence of an empty uterine cavity. Due to the serious consequences that can arise from CSP, it is essential to carry out a timely and correct diagnosis and treatment. The symptomatology of CSP is often not so specific, and this makes its diagnosis even more tricky. Moreover, about a third of patients who present with CSP are actually asymptomatic [5]. For these reasons, it is essential that every woman with a positive pregnancy test and a history of previous caesarean section undergo a transvaginal ultrasound during the first trimester of pregnancy. Among differential diagnosis, it is important to exclude a cervical pregnancy or a missed miscarriage [6]. Due to the rarity of CSP, the optimal treatment has not been already established. The surgical approach was previously considered the only possible treatment of these cases. In addition, there is no consensus regarding the optimal treatment for women who wish to avoid the surgical procedure and individualized therapy should be performed. Moreover since most of these women may wish to conceive again, it is remarkable the necessity to found conservative treatment options in order to preserve the surgical modality for cases of uncontrolled bleeding [7]. The aim of this article is to present a review of the literature about CSP and to report a case of a caesarean scar pregnancy successfully treated with uterine artery methotrexate (MTX) infusion and embolization.

Case Presentation

A 38-year-old woman, G3P1, underwent a routine early pregnancy scan in Aosta Beauregard Hospital in October 2022. The pregnancy followed a spontaneous conception. The patient underwent a surgically management of termination of pregnancy one year before and a caesarean section for fetal distress four years before. After a transvaginal ultrasound, she was diagnosed with a cesarean scar pregnancy. At the time of the visit, the serum free-$\beta$-human chorionic gonadotropin ($\beta$-hCG) values were elevated as in normal pregnancy and there were no signs or symptoms of an ectopic pregnancy. A transvaginal ultrasound was performed, with the findings of a six weeks’ gestational age vital embryo with a crown-rump length (CRL) of 6 mm. Moreover, it was noted that the gestational sac was implanted at the level of the previous cesarean scar. The images of pelvis magnetic resonance imaging (MRI) performed during the hospital stay, confirmed the presence of a gestational sac with a diameter of 25 mm, embedded in the anterior lower uterine wall, in close contact with the perimetrium. (Figure 1 and 2). The levels of serum hemoglobin and $\beta$-hCG were 13.2g/dL and 14643 UI/L, respectively. After an adequate counseling of the patient, she agreed for an intervention treatment. In agreement with the patient, a bilateral uterine arteries methotrexate infusion and embolization was performed. Firstly, catheterization was performed through both right and left femoral arteries in order to reach uterine arteries; then an intra-arterial injection of 50 mg of MTX (first MTX dose), followed by gelatin sponge and non-resorbable microspheres (700-900 micron) for bilateral uterine artery occlusion were administrated. After the procedure, the uterus appeared de-vascularized. No side effects nor complications were noted. Later on, three doses of MTX were administrated intramuscularly every following days (days 3, 5, 7). During the in-hospital follow-up period, the patient underwent repeated measurements of $\beta$-hCG (on days 5, 7 and 9) and was closely monitored for symptoms and clinical or sonographic signs of pregnancy rupture or hemodynamic instability. The day after the embolization, a transvaginal scan showed a 14.4 mm sized gestational sac implanted at the level of the previous cesarean scar. The fetal heart activity was absent. Serum $\beta$-hCG declined to a level of 7858 UI/L on the fourth post-procedure day and 5655 UI/L on the sixth day. One week after the embolization, another transvaginal scan was performed showing no differences in the gestational sac size. Although this, the sac was noted as closer to the cervical canal. Poor vaginal bleeding was recorded. At this point, vaginal prostaglandin (3 doses of Gemeprost every four hours) was administrated. After 3 administrations, an ultrasound guided dilatation and curettage was performed without further complications. The post-procedure transvaginal scan showed no more gestational material within the endometrial cavity. The patient was discharged after 24 hours of follow-up without complications; the $\beta$-hCG level was 4247 UI/L. Summarily, the hospitalized period was 9 days. Seven days after the discharge, $\beta$-hCG was declined to a level of 989 UI/L and a month after the embolization it was 24.9 UI/L.
Discussion

Caesarean scar pregnancy represents 6.1% of all ectopic pregnancies after cesarean deliveries [3,4]. The incidence varies from 1/1800 to 1/2226, occurring in 1.15% of women with previous cesarean deliveries [3,4]. Few cases of cesarean scar pregnancies are reported within the living literature, although an increase in the caesarean section rate during the last years [3,4]. Caesarean incisions usually heal without any complications. In the past several years, some authors described cesarean scar defects on transvaginal ultrasonography as a wedge-shaped anechoic area suggesting possible impaired healing [2]. The prevalence of cesarean scar defects in a random population of women is up to 84% and is usually asymptomatic [2]. Some authors evaluated the histopathology of uterine wound healing and found different thicknesses of the myometrium along the scar with disordered muscular fibers and elastosis. [2] Although the mechanism is not clear, it seems that impaired healing of the cesarean incision predisposes to the development of CSP. Factors predisposing to poor wound healing include inadequate closure of the uterine incision, postoperative infections, impaired health conditions such as diabetes or collagen disturbances. Decreased blood flow to the affected tissues predispose to incomplete or delayed healing. Nevertheless, it remains unclear if the technique of the uterine closure during cesarean section (either single or double uterine closure) correlates with the occurrence of CSP [2]. It is difficult to identify the optimal management in individual cases. If an expectant attitude is assumed, CSP will probably transform into a pregnancy with placenta percreta in the scar and in the lower segment. Considering the possible consequences, early diagnosis and treatment offer much better prognosis. When making a decision about the management in CSP, the following must be considered: size of pregnancy, presence or absence of uterine continuity, β-hCG level, wish to remain fertile and patient’s hemodynamic state [8,9]. A conservative treatment should be offered to women who wish to conceive again. The conservative treatment options can be categorized as: reduction of blood supply, systemic chemotherapy, and local chemotherapy or fetocide [10]. The most commonly used methods are systemic MTX (33.9%), uterine artery embolization (21.9%), dilatation and curettage (14.1%), hysterotomy (10.6%) and hysteroscopy (6.7%). Combined treatment methods are applied more rarely: TA US or TV US + local MTX treatment in 6.6% of cases, TV US + gestational sac aspiration in 3.7% of cases, TV US or TA US + local injection of vasopressin or potassium chloride in 1% of cases, and bilateral hypogastric artery ligation in 0.1% of cases. Dilatation and curettage with subsequent intrauterine Foley catheter insertion may be recommended, but only due to its availability, simplicity and relatively high efficacy. However, bearing in mind significant risk of hemorrhage and high risk of secondary hysterectomy and fertility loss, this form of treatment should only be used in selected cases of early diagnosed CSP [11,12]. Conservative treatment with systemic methotrexate (MTX) alone has shown favorable results in non-tubal ectopic pregnancies, although the effectiveness of this treatment decreased dramatically in high (>10,000 IU/L) levels of beta-human chorionic gonadotropin (β-HCG) or in cases with fetal cardiac activity [6,10,13]. The failure rates of monotherapy with MTX, in fact, is approximately 57% in CS scar pregnancies [14]. It has been proposed that simultaneous systemic and local MTX administration for CSP with β-hCG levels above 10,000 mLU/mL may be a very effective method that does not require further interventions. Systemic MTX administration seems to be the most effective for CSP with β-hCG below 5,000 IU/mL, and should be limited to two doses, 1 mg/kg body weight each, to avoid adverse effects. In the case of systemic MTX therapy, serial color Doppler scans are useful for CSP monitoring and seem to correlate well with serum beta hCG [12]. It therefore appears that systemic methotrexate treatment should not be applied on the routine basis due to relatively low efficacy, high
risk of hysterectomy and fertility loss, and the risk of various adverse effects. On the other hand, local methotrexate therapy (under ultrasound or hysteroscopy guidance) should be considered a perfect management method as it offers fertility preservation in asymptomatic pregnant patients without concomitant hemodynamic disorders. The most effective CSP treatment is simultaneous application of 2–3 techniques [11,12]. Uterine artery embolization (UAE) is currently used in obstetrics and gynecology as a treatment modality for uterine fibroids or to control obstetric haemorrhage. Recently, this modality was considered when treating non-tubal ectopic pregnancies [15,16,17], particularly in cases when the trophoblasts are deeply embedded in myometrium. Previous reports, however, had a relatively small sample size [8], or used it in combination with other surgical procedures (e.g. dilation and curettage) to control bleeding and in many cases, an emergency surgical procedure and even hysterectomy were unavoidable [8,9,17]. The MTX infusion during the UAE allows to further decreasing blood HCG level. Since monotherapy with either systemic MTX or UAE has shown only moderate success rates, some studies analysed the effectiveness and safety of uterine artery MTX infusion and embolization combined with systemic MTX for treatment of non-tubal ectopic pregnancy in women who wish fertility preservation and desire to avoid surgical treatment. [18]. The conservative treatment protocol applied in this case report included a total of 4 MTX doses. The first one was administered during the percutaneous catheterization of the femoral artery by intra-arterial injection of 50 mg of MTX, just before injecting gelatin sponge and non-resorbable microspheres (700-900 micron) for bilateral uterine artery occlusion. The remaining 3 doses were given intramuscularly every other day. The rationale for this treatment protocol, as underlined by Krissi et al [18], was to increase the success rate of conservative treatment by combining two modalities, each with moderate effectiveness. The hospital stay period was 9 days, in accordance with previous studies [19].

Conclusions

This case report seems to confirm that the combination therapy of uterine artery methotrexate infusion and embolization together with systemic MTX can be considered as a safe and effective treatment of cesarean-scar pregnancies.

Authors Contributions: M.N Conceptualization and Writing original draft ; A.M Writing original draft; B.M Supervision and Writing review & editing; R.T Data curation, Formal Analysis, R.TMethodology ; L.L Supervision, Writing review & editing; A.L. supervision, review & editing

Funding: None

Disclosure of Interests: None declared

References


